On the established clinical benefit of PD-1/PD-L1 inhibitors in cervical cancer, the Food and Drug Administration (FDA) has approved pembrolizumab for patients with recurrent or metastatic cervical cancer with disease progression during or after chemotherapy. This evidence concerns the gene PDCD1 and cervical carcinoma.